# FAT1

Source: https://onco.cc/targets/fat1/  
OnCo record `fat1` (Target). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

FAT1 (Protocadherin Fat 1) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Head and neck squamous cell carcinoma, Lung cancer, Bladder & urothelial cancer and 5 more.

## Summary

Plays an essential role for cellular polarisation, directed cell migration and modulating cell-cell contact.

CIViC holds 1 clinical evidence item and 0 assertions across 1 variant, naming CDK4/6 Inhibition. Open Targets scores its association with cancer at 0.78 (direct and indirect evidence; datatypes affected pathway 0.61, literature 0.99, genetic association 0.18, somatic mutation 0.98, animal model 0.44). IntOGen calls it a driver in 45 cohorts (15 activating, 30 loss-of-function), covering Acute Myeloid Leukaemia, Angiosarcoma, Anal Squamous Cell Carcinoma, Basal Cell Carcinoma, Burkitt Lymphoma, Bladder/Urinary Tract and others.

## Fields

- Kind: Target
- Last checked: 2026-09-23
- Also known as: FAT atypical cadherin 1; Protocadherin Fat 1; CDHF7; CDHR8
- Tags: cancer-genes-wave
- Symbol: FAT1
- Class: tumor-suppressor
- Biology: Plays an essential role for cellular polarisation, directed cell migration and modulating cell-cell contact. Location: Cell membrane; Nucleus (UniProt). Locus 4q35.2 (HGNC).
- Where found: Head and neck squamous cell carcinoma: Open Targets association 0.70 with head and neck squamous cell carcinoma (MONDO_0010150); IntOGen driver in 5 cohorts (HNSC); Lung cancer: Open Targets association 0.68 with lung cancer (MONDO_0008903); Bladder & urothelial cancer: Open Targets association 0.60 with urinary bladder cancer (MONDO_0001187); IntOGen driver in 7 cohorts (BLADDER, BLCA, UTUC); Breast cancer: CIViC evidence names this disease; IntOGen driver in 1 cohort (BRCA); Oesophageal cancer: Open Targets association 0.59 with oesophageal cancer (MONDO_0007576); IntOGen driver in 2 cohorts (ESCA, ESCC); Cervical cancer: Open Targets association 0.53 with cervical cancer (MONDO_0002974); IntOGen driver in 2 cohorts (CESC)

## Notes

- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: CIViC lists 1 therapies; IntOGen calls it an activating (Act) driver in 15 cohorts; IntOGen calls it a loss-of-function (LoF) driver in 30 cohorts; CIViC holds 1 clinical evidence items on its variants. Evidence tier "clinical-evidence" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.

## Sources

- HGNC HGNC:3595: https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3595
- UniProt Q14517: https://www.uniprot.org/uniprotkb/Q14517/entry
- NCBI Gene 2195: https://www.ncbi.nlm.nih.gov/gene/2195
- Ensembl ENSG00000083857: https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000083857

## Connected records

- collections: [CIViC](https://onco.cc/collections/civic/), [IntOGen](https://onco.cc/collections/intogen/), [Open Targets Platform](https://onco.cc/collections/open-targets/)
- cancers: [Bladder & urothelial cancer](https://onco.cc/cancers/urothelial/), [Breast cancer (all types)](https://onco.cc/cancers/breast-cancer/), [Cervical cancer](https://onco.cc/cancers/cervical/), [Head and neck squamous cell carcinoma](https://onco.cc/cancers/head-and-neck/), [Lung cancer (all types)](https://onco.cc/cancers/lung-cancer/), [Nasopharyngeal carcinoma](https://onco.cc/cancers/nasopharyngeal/), [Oesophageal cancer](https://onco.cc/cancers/esophageal/), [Pancreatic ductal adenocarcinoma](https://onco.cc/cancers/pancreatic/)

---
JSON: https://onco.cc/api/v1/entities/fat1.json